Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T c

Trial has advanced to the fourth and final dose escalation cohort with no dose-limiting toxicities observed to-dateTevogen’s investigational T cell product is genetically unmodified and target-specificThe enrollment is expected to conclude in the second quarter of 2022WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio, a la...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Dolores Grosso ,Tevogen Bio ,Ryan Saadi ,Zinc The Company ,Jefferson Health Institutional Review Board ,Data Safety Monitoring Committee ,Jefferson University Hospitals ,Cytokine Release Syndrome ,Safety Monitoring Committee ,Principal Investigator ,Jefferson University ,